Results 211 to 220 of about 216,694 (240)

Late‐onset and young‐onset relapsing‐remitting multiple sclerosis: evidence from a retrospective long‐term follow‐up study

European Journal of Neurology, 2018
Late‐onset multiple sclerosis (MS) has a prevalence of about 10–20% in natural history MS studies. Few data have been published about the long‐term disease trajectory in the cohort of late‐onset relapsing‐remitting MS (LORRMS).
E. D’Amico, Francesco Patti, A. Zanghì, C. Chisari, S. Fermo, Mario Zappia   +5 more
semanticscholar   +1 more source

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

Neurology, 1995
K. Johnson, B. Brooks, Jeffrey A. Cohen, C. Ford, Jill M. Goldstein, R. Lisak, L. Myers, H. Panitch, J. Rose, R. Schiffer, T. Vollmer, L. Weiner, J. Wolinsky   +12 more
semanticscholar   +1 more source

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

The Lancet, 2012
J. Cohen, A. Coles, Douglas L Arnold, C. Confavreux, E. Fox, H. Hartung, E. Havrdová, Krzysztof W Selmaj, Howard L. Weiner, E. Fisher, Vesna V. Brinar, G. Giovannoni, M. Stojanovic, Bella I Ertik, S. Lake, D. Margolin, M. Panzara, D. Compston   +17 more
semanticscholar   +1 more source

Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion

Annals of Neurology, 2004
M. Barnett, J. Prineas
semanticscholar   +1 more source

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

, 1998
G. Ebers
semanticscholar   +1 more source

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Lancet Neurology, 2014
P. Calabresi, E. Radue, D. Goodin, D. Jeffery, K. Rammohan, A. Reder, T. Vollmer, M. Agius, L. Kappos, T. Stites, Bingbing Li, L. Cappiello, P. von Rosenstiel, F. Lublin   +13 more
semanticscholar   +1 more source

Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis

Drugs, 2020
Yahiya Y. Syed
semanticscholar   +1 more source

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis

Journal of Neurology, 2019
Huihui Li, Fengli Hu, Yanli Zhang, Kai Li   +3 more
semanticscholar   +1 more source

Altered intestinal permeability in patients with relapsing–remitting multiple sclerosis: A pilot study

Multiple Sclerosis, 2017
M. Buscarinu, Benedetta Cerasoli, Viviana Annibali, Claudia Policano, L. Lionetto, M. Capi, R. Mechelli, S. Romano, A. Fornasiero, Gianluca Mattei, Eleonora Piras, D. Angelini, L. Battistini, M. Simmaco, R. Umeton, M. Salvetti, G. Ristori   +16 more
semanticscholar   +1 more source

Multiple Sclerosis

New England Journal of Medicine, 1982
Henry F Mcfarland, Dale E Mcfarlin, Mcfarland Henry F   +2 more
exaly   +2 more sources